Johnson & Johnson MedTech Grows 5.4% to $34B, Cardiovascular Up 15.8%
Johnson & Johnson’s MedTech unit posted $34 billion in 2025 sales, up 5.4%, and cardiovascular revenues rose 15.8% to $8.9 billion after Shockwave and Abiomed acquisitions. J&J expects stronger MedTech growth in 2026 from VARIPULSE, ETHICON4000 and OASYS MAX launches, but warns of $500M in tariff costs and China procurement headwinds.
1. 2025 MedTech Performance
The MedTech unit accounted for 36% of total revenue in 2025, generating $34 billion in sales, a 5.4% operational increase supported by 15 major new product launches across orthopedics, surgery, cardiovascular and vision markets.
2. Cardiovascular Segment Growth
Cardiovascular sales reached $8.9 billion, up 15.8% in 2025, as acquisitions of Shockwave in 2024 and Abiomed in 2022 positioned J&J as a category leader in key high-growth intervention markets.
3. 2026 Outlook and Headwinds
For 2026, J&J anticipates accelerated MedTech growth fueled by VARIPULSE in electrophysiology, ETHICON4000 in surgery and the OASYS MAX family in vision, while flagging $500 million in additional tariff costs and persistent procurement headwinds in China.
4. Orthopedics Spin-off Plans
J&J plans a potential spinoff of its Orthopaedics franchise into a standalone company, DePuy Synthes, by mid-2027 to streamline its portfolio and boost long-term growth and margins, addressing the slow-growth nature of its orthopedics business.